Editas Medicine Announces Breakthrough in In Vivo Gene Editing for Sickle Cell Disease and Beta Thalassemia at European Hematology Association 2025 Congress
Editas Medicine, Inc., a leading gene editing company, has announced the presentation of new in vivo data at the European Hematology Association 2025 Congress. The data demonstrates therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells using a single dose of proprietary targeted lipid nanoparticle delivery in non-human primates. This approach, which aims to upregulate fetal hemoglobin, is in pre-clinical development for treating sickle cell disease and beta thalassemia. The results, which achieved a 58% mean editing rate at five months post-treatment, will be detailed in a poster session scheduled for June 14, 2025, at the Allianz MiCo, Milano Convention Centre. A presentation of these findings is currently available on the Editas Medicine website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467368-en) on June 12, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。